All In Biotech

Drug Trial Radar · NCT02285036

Safety and Immunogenicity of a Newly 23-valent Pneumococcal Polysaccharide Vaccine in Chinese Adults and Children

A Phase III Clinical Trial for a Newly 23-valent Pneumococcal Polysaccharide Vaccine in Chinese Adults and Children

Last checked: Nov 19, 2026Latest source record: Nov 6, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,660 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,660

Actual

Start

Sep 2012

Primary completion

Dec 2012

Study completion May 2013

Sponsor

Lead sponsor
Walvax Biotechnology Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Guangxi Center for Disease Control and Prevention; Air Force Military Medical University, China
First posted
Nov 6, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Prevention
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A newly 23-valent pneumococcal polysaccharide vaccine was developed with promising safety and immunogenicity demonstrated in the phase III trial in China. A large scale, double blind, randomized, PNEUMOVAX 23 (Merck \& Co., Inc.) controlled phase 3 clinical trial was conducted.

Conditions

  • Pneumococcal Infectious Diseases

Interventions

  • vaccination PPV23Biological

    All eligible participants were stratified into four age strata namely, 2 to 6 years, 7 to 17 years, 18 to 59 years and more than 60 years. Stratified, block randomization with a size of eight was applied. Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1. Blood samples were obtained from each subject at baseline, day 30-35 after injection, to evaluate immunogenicity.

  • vaccination PNEUMOVAX 23Biological

    Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the rate of 2-fold increase of anti-pneumococcal antibodyTime frame: 30 days after the injection of vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Guangxi Provincial Center for Diseases Control and Prevention

    Nanning, Guangxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.